New World Health Organization recommendations for care of preterm or low birth weight infants: health policy

Darmstadt, Gary L.; Al Jaifi, Nafisa Hamoud; Arif, Shabina; Bahl, Rajiv; Blennow, Mats; Cavallera, Vanessa; Chou, Doris; Chou, Roger; Comrie-Thomson, Liz; Edmond, Karen; Feng, Qi; Riera, Patricia Fernandez; Grummer-Strawn, Lawrence; Gupta, Shuchita; Hill, Zelee; Idowu, Ayede Adejumoke; Kenner, Carole; Kirabira, Victoria Nakibuuka; Klinkott, Reinhard; De Leon-Mendoza, Socorro; Mader, Silke; Manji, Karim; Marriott, Rhonda; Morgues, Monica; Nangia, Sushma; Portela, Anayda; Rao, Suman; Shahidullah, Mohammod; Tran, Hoang Thi; Weeks, Andrew D.; Worku, Bogale; Yunis, Khalid

doi:10.1016/j.eclinm.2023.102155

Cited by 18 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interplay and complexity of these causes are indicative of the multifactorial etiology of PTB. The National Institute for Health and Care Excellence (NICE) based in the UK and the WHO have published guidelines to support clinical staff to better identify risk factors for PTB in early pregnancy and offer evidence-based interventions [54,55]. In addition to recommending methods to modify risk, as well as methods of surveillance of high-risk groups, they also provide guidance on the nature of obstetric and neonatal support that should be available to patients in the acute setting where PTB is inevitable.…”

Section: Risk Factors and Pathophysiology Of Preterm Birthmentioning

confidence: 99%

Does Precision-Based Medicine Hold the Promise of a New Approach to Predicting and Treating Spontaneous Preterm Birth?

Khan,

Singh,

Yovera Leyva

et al. 2024

IJTM

View full text Add to dashboard Cite

Background: Preterm birth (PTB) is a leading cause of childhood disability, and it has become a key public health priority recognized by the World Health Organization and the United Nations. Objectives: This review will: (1) summarize current practice in the diagnosis and management of PTB, (2) outline developments in precision-based medicine for diagnostics to improve the care provided to pregnant women at risk of PTB, and (3) discuss the implications of current research in personalized medicine and the potential of future advances to influence the clinical care of women at risk of PTB. Methodology: This is a narrative literature review. Relevant journal articles were identified following searches of computerized databases. Key Results: Current and emerging technologies for the utility of personalized medicine in the context of PTB have the potential for applications in: (1) direct diagnostics to identify and target infection as one of the main known causes of PTB, (2) identifying novel maternal and fetal biomarkers, (3) the use of artificial intelligence and computational modeling, and (4) combining methods to enhance diagnosis and treatment. Conclusions: In this paper, we show how current research has moved in the direction of the targeted use of biomarkers in the context of PTB, with many novel approaches.

show abstract

Section: Risk Factors and Pathophysiology Of Preterm Birthmentioning

confidence: 99%

Does Precision-Based Medicine Hold the Promise of a New Approach to Predicting and Treating Spontaneous Preterm Birth?

Khan,

Singh,

Yovera Leyva

et al. 2024

IJTM

View full text Add to dashboard Cite

show abstract

“…Similarly, the American Gastroenterological Association recommends conditional use of Lactobacillus spp and Bifidobacterium spp in preterm infants for the prevention of NEC [ 25 ]. The WHO also recently published a new recommendation that probiotics formulated for preterm or low birthweight infants be considered for use in infants <32 weeks gestation who are fed human milk [ 26 ]. Despite the recent AAP statement, probiotics continue to be used in NICUs across the US.…”

Section: Introductionmentioning

confidence: 99%

Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

Wala,

Ragan,

Pryor

et al. 2024

J Perinatol

View full text Add to dashboard Cite

Objective In 2015, 14.0% of US NICUs administered probiotics to very low birth weight infants. Current probiotic use prior to and after the Fall of 2023 (when FDA warnings were issued) remains unknown. Study design A survey was distributed to the American Academy of Pediatrics Section on Neonatal and Perinatal Medicine (August–November/2022) and Neonatology Solutions’ Level III/IV NICUs (January–April/2023). Probiotic administration practices were investigated. Results In total, 289 unique NICUs and 406 providers responded to the survey. Of those, 29.1% of NICUs administered prophylactic probiotics to premature neonates, however, this decreased considerably after FDA warnings were issued. Additionally, 71.4% of providers stated willingness to administer probiotics to premature infants if there was an FDA-approved formulation. Conclusions Probiotic use in US NICUs increased between 2015 and the Fall of 2023 and then dropped dramatically following warning letters from the FDA. The introduction of an FDA-approved probiotic may further expand administration.

show abstract

“…In China, the rate of preterm birth is also on the rise ( 4 ). Each year, approximately 1.1 million newborns die from preterm birth ( 5 ) and its related complications, including respiratory distress syndrome ( 6 ), apnea ( 7 ), metabolic disorders, anemia, and feeding intolerance ( 8 ). Even infants who survive may suffer from long-term sequelae such as growth retardation, chronic lung disease, cerebral palsy, and more, posing a significant economic burden on families and society ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Maternal cobalt concentration and risk of spontaneous preterm birth: the role of fasting blood glucose and lipid profiles

Huang,

Zheng,

Wang

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

IntroductionSpontaneous preterm birth (SPB) is a significant cause of neonatal mortality, yet its etiology remains unclear. Cobalt, an essential trace element, might be a risk factor for SPB. This study aims to investigate the relationship between maternal serum cobalt concentration and SPB, and to clarify the role of blood lipids and fasting blood glucose (FBG) in this relationship.MethodsWe conducted a nested case-control study within the Beijing Birth Cohort Study. Serum samples were obtained from 222 pregnant women with SPB and 224 controls during the first (7–13 weeks of pregnancy) and third trimesters (32–42 weeks of pregnancy). Serum cobalt concentration was determined using inductively coupled plasma mass spectrometry (ICP-MS). Fasting blood glucose and lipids levels were detected using a fully automated biochemical immunoassay instrument. Logistic regression models and linear regression models were established to explore the association between serum cobalt concentration and the risk of SPB in pregnant women, and to test the mediating effect of fasting blood glucose (FBG) and lipids.ResultsWe found that the serum cobalt concentration in mothers with SPB and controls was similar in the first trimester, with values of 0.79 (0.58–1.10) ng/mL and 0.75 (0.51–1.07) ng/mL, respectively. However, in the third trimester, the cobalt concentration increased to 0.88 (0.59–1.14) ng/mL and 0.84 (0.52–1.19) ng/mL, respectively. In the logistic regression model, when considering the third trimester of pregnancy, after adjusting for ethnicity, pre-pregnancy body mass index (BMI), maternal age, education, income, and parity, it was observed that the medium level of cobalt concentration (0.63–1.07 ng/ml) had a negative correlation with the risk of SPB. The odds ratio (OR) was 0.56, with a 95% confidence interval of 0.34–0.90 ng/mL and a p-value of 0.02. This suggests that cobalt in this concentration range played a protective role against SPB. Additionally, it was found that FBG in the third trimester of pregnancy had a partial intermediary role, accounting for 9.12% of the association. However, no relationship between cobalt and SPB risk was found in the first trimester.ConclusionDuring the third trimester, intermediate levels of maternal cobalt appear to offer protection against SPB, with FBG playing a partial mediating role. To further clarify the optimal cobalt concentrations during pregnancy for different populations, a multi-center study with a larger sample size is necessary. Additionally, exploring the specific mechanism of FBG’s mediating role could provide valuable insights for improving the prevention of SPB.

show abstract

New World Health Organization recommendations for care of preterm or low birth weight infants: health policy

Cited by 18 publications

References 41 publications

Does Precision-Based Medicine Hold the Promise of a New Approach to Predicting and Treating Spontaneous Preterm Birth?

Does Precision-Based Medicine Hold the Promise of a New Approach to Predicting and Treating Spontaneous Preterm Birth?

Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

Maternal cobalt concentration and risk of spontaneous preterm birth: the role of fasting blood glucose and lipid profiles

Contact Info

Product

Resources

About